Researchers have made a significant breakthrough in progressive multiple sclerosis treatment by identifying six protein targets that could reshape therapeutic approaches for this devastating neurological condition. The study, published in a peer-reviewed medical journal, reveals that these specific molecular pathways represent promising avenues for targeted intervention. Beyond the protein targets themselves, scientists have identified 13 existing drugs with potential for repurposing in progressive MS therapy. This discovery is particularly significant given that progressive forms of MS remain among the most challenging variants to treat, affecting millions of patients worldwide who currently face limited therapeutic options. The research suggests that targeted approaches based on specific protein pathways may offer superior efficacy compared to conventional broad-spectrum treatments, offering renewed hope for the estimated 2.8 million MS patients globally. Read the full article on GMJ Newsroom.
Was this article helpful?
